Karyopharm Therapeutics Inc. · NASDAQ:KPTI
Karyopharm Therapeutics — Q3 2020 Earnings Presentation
21 slides from Karyopharm Therapeutics's earnings presentation, Nov 2, 2020
Slide 1: Investor Conference Call: Third Quarter 2020 Financial Results and Business Update
Investor Conference Call: Third Quarter 2020 Financial Results and Business Update November 2, 2020
Slide 2: On Today's Call
On Today’s Call • Michael G. Kauffman, MD, PhD, Chief Executive Officer Prepared • John Demaree, Chief Commercial Officer Remarks • Mike Mason, MBA, Chief Financial Officer • Sharon Shacham, PhD, President and Chief Scientific Officer Joining for • Jatin Shah, MD, Executive Vice President, Chief Med
Slide 3: Forward-looking Statements and Other Important Information
Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s expectations and plans relating to XPOVIO
Slide 4: Core Pillars of Cancer Drug Therapy
Core Pillars of Cancer Drug Therapy CHEMO- TARGETED TUMOR VASCULAR- IMMUNO- THERAPY AGENTS SUPPRESSOR TARGETING THERAPY PROTEIN ACTIVATION Harnessing the body’s own natural defense mechanisms ©2020 Karyopharm Therapeutics Inc. 4
Slide 5: Karyopharm Near and Medium-Term Corporate Goals
Karyopharm Near and Medium-Term Corporate Goals Next 3-5 Years (2023-2025) Next 1-2 Years • Increasing impact on the lives of patients battling (2021-2022) cancer • Increasing impact on the lives of patients battling cancer • Additional indication approvals for XPOVIO, including in solid tumors, acr
Slide 6: Solid Tumor Update: SEAL Phase 3 Positive Top-Line Results
Solid Tumor Update: SEAL Phase 3 Positive Top-Line Results: • Study met primary endpoint with significant increase in progression-free survival in patients with unresectable dedifferentiated liposarcoma following at least two prior therapies Top-Line • Hazard ratio=0.70; p=0.023 Phase 3 Data • Safet
Slide 7: Innovation with a Purpose: Demonstrate Meaningful Activity and Then Expand
Innovation with a Purpose: Demonstrate Meaningful Activity in Difficult to Treat Patient Populations and Then Expand, Dramatically 2nd Line+ multiple 2nd Line+ DLBCL Broad utility across Significant myeloma in combination in combination with numerous solid Growth with standard of care standard of ca
Slide 8: Another Record Quarter for XPOVIO Sales and Key Development Milestones Achieved
Another Record Quarter for XPOVIO Sales and Key Development Milestones Achieved Pipeline / Clinical Corporate Development Commercial Update Data Update and Balance Sheet • Q3 2020 XPOVIO net sales of $21.3M • Phase 3 SEAL study meets primary • Sharon Shacham, Founder, President, marking highest quar
Slide 9: Most Impactful Features of XPOVIO for Physicians Treating Relapsed Refractory Multiple Myeloma
Most Impactful Features of XPOVIO for Physicians Treating Patients with Relapsed Refractory Multiple Myeloma1 Feature Details Patients rapidly responded to XPOVIO combination 1. Rapid response therapy (STORM study) at a median of 4 weeks, with some responses as early as 1 week 2. Meaningful overall
Slide 10: XPOVIO 2020 Quarterly Sales and Prescription Trends
XPOVIO 2020 Quarterly Sales and Prescription Trends XPOVIO Product Sales and RXs in 2020 • 15% increase in both net sales and patient demand $21.3M in Q3 2020 compared to $18.6M Q2 2020 Net Sales ($M) Inventory Sales Inventory Sales +15% • Robust increase in new $16.1M (Sales) multiple myeloma patie
Slide 11: XPOVIO Prescriber Base Continues to Grow
XPOVIO Prescriber Base Continues to Grow New Accounts Prescribing XPOVIO in 2020 202 170 171 543 New Accounts Q1 2020 Q2 2020 Q3 2020 Note: Q3 2020 includes both multiple myeloma and DLBCL treating physicians ©2020 Karyopharm Therapeutics Inc. 11
Slide 12: Key XPOVIO Patient Metrics Demonstrate Positive Trends
Key XPOVIO Patient Metrics Demonstrate Positive Trends Prescription Refill Rate for 1st and 2nd Prescription (Only Includes Patients Eligible for a Refill)1 Average Treatment Cycles Average (RXs) Treatment C Per Patient = % of Patients Refilling a RX 61% 60% 2.91 57% 57% 56% 56% 42% 52% 52% Patient
Slide 13: Key Metrics and Insights from DLBCL Launch
Key Metrics and Insights from DLBCL Launch Early Launch Metrics Physician Feedback / Early Market Dynamics • Two-thirds of XPOVIO DLBCL prescriptions to date • Target physicians most attracted to XPOVIO’s have come from community-based physicians response rate as a single agent, oral option, and ─ 7
Slide 14: Regulatory Update Across Potential Future Indications
Regulatory Update Across Potential Future Indications • U.S. BOSTON sNDA ─ FDA has assigned an action date of March 19, 2021 under the Prescription Drug User Fee Act (PDUFA) ─ Review process is actively progressing ─ Potential to expand multiple myeloma indication in the U.S. from penta-refractory s
Slide 15: Key Future Inflection Point: Potential XPOVIO Label Expansion Based on BOSTON Study
Key Future Inflection Point for Karyopharm: Potential XPOVIO Label Expansion Based on the BOSTON Study Select Differences Between the STORM and BOSTON Studies Evaluating XPOVIO in Patients with Multiple Myeloma Median # XPOVIO Median Mean of Prior Dose ORR Progression Duration of Therapies Frequency
Slide 16: Karyopharm's Novel Pipeline | Selinexor
Karyopharm’s Novel Pipeline | Selinexor Hematologic Malignancies Phase 1 Phase 2 Phase 3 Multiple Myeloma (relapsed/refractory) | STORM FDA Approved (Accelerated Approval)1 Multiple Myeloma (relapsed/refractory) | BOSTON2 Diffuse Large B-cell Lymphoma (relapsed/refractory) | SADAL FDA Approved (Acce
Slide 17: Third Quarter Financial Results
Third Quarter Financial Results Mike Mason Chief Financial Officer
Slide 18: Third Quarter 2020 Financial Results
Third Quarter 2020 Financial Results Three Months Ended Statement of Operations Sept 30th 2020 2019 Total Revenue $21.3M $13.1M XPOVIO Net Sales $21.3M $12.8M License and Other Revenue - $0.3M Total Operating Expenses $68.4M $52.6M Cost of Sales $0.4M $1.0M Research and Development Expense $37.0M $2
Slide 19: Balance Sheet and Financial Guidance
Balance Sheet and Financial Guidance Balance Sheet September 30, 2020 December 31, 2019 Cash, Cash Equivalents, Restricted Cash $304.2M $265.8M and Investments • Non-GAAP R&D and SG&A expenses are expected to be in the range of $240-260M for the full year 20201 • Cash runway expected to be sufficien
Slide 20: Numerous Key Milestones for XPOVIO / Selinexor in 2020
Numerous Key Milestones for XPOVIO / Selinexor in 2020 Mid-Late 2020 1. BOSTON data presentation at ASCO 2020 2. sNDA submission based on data from BOSTON study 3. Regulatory decision from FDA based on DLBCL sNDA 4. U.S. commercial launch in DLBCL 5. Initial results from COVID-19 clinical trial1 Ear
Slide 21: Questions? Answers.
Questions? Answers. ©2020 Karyopharm Therapeutics Inc. 21
Karyopharm Therapeutics — Q3 2020 Earnings Presentation on 6ix